Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Clinical trial NCT07680946 · RECRUITING
Trial details
- NCT number
- NCT07680946
- Sponsor
- TG Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-03
- Primary completion
- 2028-12-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.